Abstract
Combination chemotherapy with cisplatin and pemetrexed is the most active first-line regimen for malignant pleural mesothelioma (MPM). However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse. We have now evaluated the combination of cisplatin and pemetrexed for retreatment of patients with recurrent MPM. Four men with MPM, all of whom received initial treatment with cisplatin and pemetrexed, underwent retreatment with this drug combination. Two of the patients achieved an objective response to the first-line chemotherapy with no evidence of disease progression for 6.4 or 11.4 months, respectively. The other two patients had stable disease with a duration of 7.8 or 5.0 months, respectively. The two patients who showed an objective response to first-line chemotherapy showed a partial response to retreatment, with a time to progression of 5.0 or 8.2 months, whereas the other two patients had progressive disease with a time to progression of 1.0 or 1.4 months, respectively. Retreatment with cisplatin plus pemetrexed was generally well tolerated. Retreatment with cisplatin and pemetrexed is a potential therapeutic option for certain patients with recurrent epithelioid MPM, possibly including those who show tumor regression with a time to progression of 6 months or more after the initial chemotherapy. Further studies are warranted to evaluate the efficacy of such retreatment and to clarify the criteria for patient selection.
Similar content being viewed by others
References
Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644
Paoletti P, Pistolesi M, Rusthoven JJ et al (2003) Correlation of pulmonary function tests with best tumor response status: results from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 22:659 (Abstr 2651)
Manegold C, Symanowski J, Gatzemeier U et al (2005) Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16:923–927
Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257–260
Pfisterer J, Ledermann JA (2006) Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 33:S12–S16
Razak AR, Chatten KJ, Hughes AN (2008) Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer 60:294–297
Conflict of interest statement
I. Okamoto and K. Nakagawa received honoraria from Boehringer Ingelheim. The other authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hayashi, H., Okamoto, I., Ichikawa, Y. et al. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed. Int J Clin Oncol 15, 497–499 (2010). https://doi.org/10.1007/s10147-010-0064-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-010-0064-7